MyBioSource

antibody

MOUSE ANTI HUMAN LOX-1 (SOLUBLE)

MBS214510

0.2 mg

430 USD

monoclonal

mouse

human

enzyme immunoassay, western blot, ELISA

MBS214510

Antibody

MOUSE ANTI HUMAN LOX-1 (SOLUBLE)

LOX-1

oxidized low-density lipoprotein receptor 1 isoform 2; Oxidized low-density lipoprotein receptor 1; oxidized low-density lipoprotein receptor 1; C-type lectin domain family 8 member A; hLOX-1; lectin-type oxidized LDL receptor 1; ox LDL receptor 1; oxidized low-density lipoprotein receptor 1, soluble form; scavenger receptor class E, member 1; oxidized low density lipoprotein (lectin-like) receptor 1; C-type lectin domain family 8 member A; Lectin-like oxidized LDL receptor 1; LOX-1; Lectin-like oxLDL receptor 1; hLOX-1; Lectin-type oxidized LDL receptor 1Oxidized low-density lipoprotein receptor 1, soluble form

LOX-1

OLR1; OLR1; LOX1; LOXIN; SLOX1; CLEC8A; SCARE1; CLEC8A; LOX1; Ox-LDL receptor 1; LOX-1; Lectin-like oxLDL receptor 1; hLOX-1

OLR1_HUMAN

Monoclonal

IgG2a

LOX20-7

Mouse

181

Purified. Purified IgG - liquid

IgG concentration 1.0mg/ml

Store at 4 degree C or at -20 degree C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. Shelf Life: 18 months from date of despatch.

ELISA (EIA), Western Blot (WB)

Perservative Stabilisers: 0.09% Sodium Azide (NaN3) . Preparation: Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

Immunogen: Recombinant soluble LOX-1 expressed in E Coli. Fusion Partners: Spleen cells from immunised Balb/c were fused with cells of the Sp2/0 myeloma cell line. Buffer Solution: Phosphate buffered saline. Target Species: Human

Mouse anti Human LOX-1 (Soluble) antibody, clone LOX20-7 recognizes the lectin-like oxidised low-density lipoprotein (LDL) receptor (LOX-1), a 31kDa protein of the C-type lectin superfamily. This receptor mediates the recognition, internalisation and degradation of oxidised LDL. It is a Type II membrane protein with a typical C-type lectin structure at the extracellular C-terminus which recognizes the ligand. LOX-1 activation by oxidised LDL causes endothelial changes such as decreased nitric oxide release and an increased expression of adhesion molecules. LOX-1 also binds activated platelets and apoptotic cells. The expression of LOX-1 is induced by proatherogenic conditions such as hyperlipidemia, hypertension and diabetes and as such appears to contribute to the pathogenesis of vascular disorders, particularly atherosclerosis. It can be cleaved by an unknown protease at the extracellular juxtamembrane region to release the soluble form (aa58-273) of LOX-1, recognized byMouse anti Human LOX-1 (Soluble) antibody, clone LOX20-7.

290654342

NP_001166103.1

NM_001172632.1

P78380

21,425 Da

Cell Surface Interactions At The Vascular Wall Pathway 106062!!Hemostasis Pathway 106028!!PPAR Signaling Pathway 83042!!PPAR Signaling Pathway 450!!Phagosome Pathway 153910!!Phagosome Pathway 153859

This gene encodes a low density lipoprotein receptor that belongs to the C-type lectin superfamily. This gene is regulated through the cyclic AMP signaling pathway. The encoded protein binds, internalizes and degrades oxidized low-density lipoprotein. This protein may be involved in the regulation of Fas-induced apoptosis. This protein may play a role as a scavenger receptor. Mutations of this gene have been associated with atherosclerosis, risk of myocardial infarction, and may modify the risk of Alzheimer's disease. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Feb 2010]

0.2 mg

430 USD